Encoded Therapeutics

Executive Summary

Encoded Therapeutics is a private biotechnology company headquartered in South San Francisco, pioneering genetic medicines for severe neurological disorders. Founded in 2014, the company focuses on developing adeno-associated virus (AAV)-based gene therapies that address the root cause of diseases such as Dravet syndrome, Rett syndrome, and other genetic epilepsies. By engineering novel vectors and regulatory elements, Encoded aims to achieve cell-type-specific expression and durable therapeutic benefit, potentially transforming the treatment landscape for these devastating conditions. The company's proprietary platform enables precise modulation of disease-associated genes, with a focus on pediatric populations where early intervention can prevent lifelong disability and premature mortality. Encoded has advanced multiple programs into preclinical development, with its lead candidate for Dravet syndrome (ETX101) demonstrating promising efficacy and safety in animal models. The company has raised significant venture capital from top-tier investors and has established key partnerships for manufacturing and clinical development. In 2025, Encoded expects to initiate its first-in-human clinical trial for ETX101, pending regulatory clearance. With a strong intellectual property portfolio and a seasoned management team, Encoded is well-positioned to become a leader in genetic medicines for neurological indications. The company's innovative approach and robust pipeline underscore its potential to address high unmet medical needs and generate substantial value for patients and shareholders alike.

Upcoming Catalysts (preview)

• Q4 2025Initiation of Phase 1/2 clinical trial for ETX101 in Dravet syndrome80% success
• Q2 2026IND filing for lead Rett syndrome program70% success
• Q1 2026Presentation of preclinical data for next-generation gene therapy platform at major neurology conference90% success